An Australia-based study evaluated more than 4,000 patients who underwent total joint operations. The patients received cefazolin, an antibacterial drug, and half were given another antibacterial, vancomycin, or a placebo. The research was published Oct. 19 in The New England Journal of Medicine.
Within 90 days after the surgery, 163 surgical site infections were diagnosed among the 4,113 patients. Ninety-one of 2,044 patients (4.5%) received vancomycin and 72 of 2,069 (3.5%) took a placebo.
Surgical-site infections after knee replacements and vancomycin were more common than infections after hip replacements and vancomycin: 5.7% with a second antibiotic versus 3.7% among the placebo group for knee replacements, and 3.0% versus 3.1% for hip replacements.
“Given the number of joint replacements performed in Australia and globally, our trial has answered the important [question] about whether more antibiotics are better for our patients having joint replacement surgery: with the definitive answer being ‘no,'” Trisha Peel, MD, PhD, the lead author of the study, said in a news release. “This trial will have a significant impact on practice.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
